 |
|
|
| |
Immediate versus delayed hepatitis C treatment in the United Kingdom:
A pan-genotypic cost-effectiveness analysis
|
| |
| |
Reported by Jules Levin
EASL 2019
April 10-14 Vienna
John Dillona, Dominic Mitchellb, Suchin Virabhakb, Monika Hermanssonc, Svetlana Kalabinac, Yuri Sanchez Gonzalezd a National Health Service (NHS), Tayside, UK; b Medicus Economics LLC, Boston, MA, USA; c AbbVie Ltd, Maidenhead, Berkshire, UK; d AbbVie Inc., North Chicago, IL, USA
"Assuming LTFU = 20%, the long-term risks at year 5 increased to 41.4% (CC), 18.6% (DCC), 8.9% (HCC), 2.2% (LT), and 20.8% (LrD). (Figure 2B)
Assuming no LTFU (= 0%), long-term liver-related outcomes increased with length of treatment delay. For instance, at year 5, there was an increased risk of CC of 2.7%, DCC (0.01%), HCC (1.0%), LT (0.05%), and LrD (1.0%). (Figure 2A)"
|
| |
|
|
|
|
|
